

Bosulif® (bosutinib) - Expanded indication, new formulation approval

- On September 26, 2023, the <u>FDA approved</u> Pfizer's <u>Bosulif (bosutinib)</u>, for treatment of adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosomepositive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy.
 - Bosulif was previously approved for this indication in adults only.
- Bosulif is also approved for the treatment of adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy.
- In addition to the expanded indication, the <u>FDA approved</u> a new capsule formulation of Bosulif.
 Bosulif was previously available as a tablet.
- The approval of Bosulif for the expanded indication was based on BCHILD, a non-randomized, open-label study in 28 pediatric patients with CP Ph+ CML. The study included 28 patients with resistance or intolerance to prior therapy and 21 patients with newly diagnosed Ph+ CML. Efficacy was assessed based on complete cytogenetic response (CCyR), major cytogenetic response (MCyR) and major molecular response (MMR).
 - The MCyR and CCyR among patients with newly diagnosed CP Ph+ CML were 76.2% (95% CI: 52.8, 91.8) and 71.4% (95% CI: 47.8, 88.7), respectively. The MMR was 28.6% (95% CI: 11.3, 52.3).
 - The MCyR and CCyR among patients with resistant or intolerant CP Ph+ CML were 82.1% (95% CI: 63.1, 93.9) and 78.6% (95% CI: 59.0, 91.7), respectively. The MMR was 50.0% (95% CI: 30.6, 69.4).
- The recommended dose of Bosulif for pediatric patients with newly-diagnosed CP Ph+ CML is 300 mg/m² orally once daily and the recommended dosage for pediatric patients with CP Ph+ CML that is resistant or intolerant to prior therapy is 400 mg/m² orally once daily (refer to the drug label for complete dose recommendations).
 - For patients who are unable to swallow capsules, the contents of the capsules can be mixed with applesauce or yogurt.
 - Refer to the Bosulif drug label for dosing for adults.
- Pfizer's launch plans for Bosulif capsules are pending. Bosulif capsules will be available in a 50 mg and 100 mg strength.

Optum

At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.